MarketPulse

pharmaceutical competition

27 articles
BenzingaBenzinga··Vandana Singh

Novo Nordisk's CagriSema Falls Short in Weight-Loss Trial Against Lilly's Tirzepatide

Novo Nordisk's CagriSema underperformed Eli Lilly's tirzepatide in weight-loss trials, delivering 20.2% versus 23.6% weight reduction, triggering stock declines amid intensifying obesity drug competition.
LLYNVOclinical trialtirzepatide
BenzingaBenzinga··Erica Kollmann

Novo Nordisk Stock Drops 16% After CagriSema Misses Efficacy Target

Novo Nordisk's stock fell 16% after CagriSema obesity drug failed to match Eli Lilly's tirzepatide in trial, showing weaker weight loss results and jeopardizing approval timeline.
LLYNVOclinical trialobesity market
The Motley FoolThe Motley Fool··Rich Smith

Novo Nordisk Stock Pullback Creates Entry Point for Long-Term GLP-1 Investors

Novo Nordisk stock down 67% offers entry point for long-term investors. Strong GLP-1 market position, attractive valuation metrics, and growth potential despite upcoming competition.
LLYNVOstock valuationdividend stocks
BenzingaBenzinga··Vandana Singh

Novo Nordisk Shares Decline on CagriSema Trial Setback Versus Lilly Rival

Novo Nordisk shares plunged 13% after CagriSema obesity drug trial missed non-inferiority target versus Eli Lilly's tirzepatide, threatening competitive positioning.
LLYNVOFDA approvalclinical trial
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Oral Weight-Loss Drug Expands Market Rather Than Cannibalizing Sales

Oral weight-loss drugs expand the market rather than cannibalizing injectables, attracting new patients. However, Novo Nordisk expects 2026 revenue headwinds from competition and pricing pressures.
LLYNVOGLP-1 drugspharmaceutical competition
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Pfizer's 6.3% Yield Hinges on GLP-1 Drug Data, Patent Cliff Challenges

Pfizer's 6.3% dividend yield depends on GLP-1 drug success and managing upcoming patent cliffs as it competes against rivals Novo Nordisk and Eli Lilly in obesity treatments.
PFELLYNVOdividend yieldclinical trial results
BenzingaBenzinga··Namrata Sen

Eli Lilly Stockpiles $1.5B in Experimental Weight-Loss Drug Ahead of FDA Review

Eli Lilly stockpiles $1.5B of experimental weight-loss drug orforglipron ahead of expected April FDA approval decision, signaling management confidence.
LLYNVOFDA approvalpharmaceutical competition